Recently, the cases of dermatophytosis have increased sharply, which is associated with frequent reports of chronic cases of the disease, uncommon skin manifestations, and treatment failure. Cases of emergence of resistant species in other geographical areas such as Denmark, Switzerland, and China, Belgium, Germany, Japan, Iran, Finland, Switzerland, France, Iraq and Bahrain are also known. Antifungal drug susceptibility testing for dermatophyte species has not yet been standardized. Antifungal Susceptibility Tests (AFST) are used to determine the minimum growth inhibitory concentration (MIC) of a specific drug in laboratory conditions with the aim of predicting whether a patient will respond to standard antifungal treatment or not. In the continuation of this article, we gave an overview of the antifungal sensitivity test, including its strengths and weaknesses and its role in helping to make therapeutic decisions.